Literature DB >> 15526971

Management of epilepsy in mentally retarded children using the newer antiepileptic drugs, vagus nerve stimulation, and surgery.

W Donald Shields1.   

Abstract

Clusters of seizures, prolonged seizures, and status epilepticus occur more frequently in children with multiple disabilities, and chronic seizures are more likely to be refractory to treatment. In many patients, the seizures appear to contribute to the mental retardation. Thus, if the lives of these children are to improve, seizure control is essential. However, medical treatment can interfere with cognition and cause behavioral disturbances, making life very difficult for the child and the child's family. With the introduction of 10 new antiepileptic drugs in the last decade, the treatment of epilepsy in multiply handicapped children has significantly advanced. These new antiepileptic drugs may improve seizure control, medication tolerance, or both. Although the ultimate therapeutic goal is to keep children seizure free and alert, compromises regarding medication choice and dosage are still necessary in many cases. Novel treatment options, such as the vagus nerve stimulator, may decrease seizure frequency without behavioral or cognitive side effects. In carefully selected children with specific epilepsy syndromes, epilepsy surgery can provide partial or complete relief from seizures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526971     DOI: 10.1177/088307380401900107

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Vagus nerve stimulation in the treatment of epilepsy: Payment policy perspectives.

Authors:  Saty Satya-Murti; Katie M Shepard; Sandra L Helmers
Journal:  Neurol Clin Pract       Date:  2013-10

2.  Vagal Nerve Stimulation in Epilepsy: Experiences of Participants with Cognitive Deficits.

Authors:  Eva Pipan; Alexandros Apostolou; Maria Bograkou; Petra Brooks; Patrick Vigren; Helena Gauffin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-08       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.